Lbp Am Sa Has $18.38 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Lbp Am Sa grew its holdings in Zoetis Inc. (NYSE:ZTS) by 19.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 112,801 shares of the company’s stock after buying an additional 18,483 shares during the quarter. Lbp Am Sa’s holdings in Zoetis were worth $18,379,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. PGGM Investments boosted its holdings in Zoetis by 91.8% in the fourth quarter. PGGM Investments now owns 58,528 shares of the company’s stock valued at $9,536,000 after acquiring an additional 28,005 shares during the last quarter. Lazard Freres Gestion S.A.S. boosted its holdings in Zoetis by 20.6% in the fourth quarter. Lazard Freres Gestion S.A.S. now owns 1,074,865 shares of the company’s stock valued at $175,127,000 after acquiring an additional 183,912 shares during the last quarter. Skandinaviska Enskilda Banken AB publ boosted its holdings in Zoetis by 9.4% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 376,173 shares of the company’s stock valued at $61,030,000 after acquiring an additional 32,204 shares during the last quarter. Erste Asset Management GmbH boosted its holdings in Zoetis by 42.9% in the fourth quarter. Erste Asset Management GmbH now owns 142,387 shares of the company’s stock valued at $23,298,000 after acquiring an additional 42,764 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Zoetis in the fourth quarter valued at about $8,710,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. The trade was a 2.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,862 shares of company stock worth $312,254. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Piper Sandler boosted their target price on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Finally, Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $215.90.

Zoetis Price Performance

Shares of ZTS opened at $160.03 on Friday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock has a 50 day simple moving average of $166.86 and a 200 day simple moving average of $176.33. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33. The firm has a market capitalization of $71.66 billion, a PE ratio of 29.26, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.